Amazon affiliate link
Alcohol pads
MED PRIDE, 70% isopropyl, 200 count per listing. An alcohol pad does not establish sterility of a research product.
View on Amazon ↗Research blends
Tesamorelin + Ipamorelin Blend
research guide
This product combines tesamorelin, an FDA-approved GHRH analog for a specific HIV-related indication, with ipamorelin, an unapproved growth hormone secretagogue, in a single vial. No clinical or preclinical study of this combined formulation was located in the Europe PMC search conducted for this page. The evidence summarized here concerns tesamorelin and ipamorelin as separately studied compounds, not the combined product, and should not be read as blend-specific evidence.
Component studies do not validate this commercial blend. Literature summary, not clinical peer review.
Looking for the product? Reign listings and business disclosure ↓
Jorge Abreu is not a doctor. This is an educational research summary, not a prescription or a personal dosing plan. Study results do not establish that a supplier product is safe or effective for people. Consult a licensed clinician about medical decisions.
01 · Start with identity
What is Tesamorelin + Ipamorelin Blend?
Tesamorelin as approved (Egrifta) and tesamorelin as sold in this research blend are not the same regulatory product; the approved drug is manufactured and dosed as a single-agent injection for a defined patient population, while this blend combines the same peptide sequence, research-grade, with ipamorelin in one vial for laboratory use, a combination not evaluated in the cited trials.
Also searched as: Tesa/Ipa combination vial
02 · Read the evidence
What the studies reported
01
Tesamorelin alone, HIV lipodystrophy trials
Phase 3 randomized trials of tesamorelin alone, in HIV patients with abdominal fat accumulation, found visceral fat reduction meeting the FDA-defined response threshold in a majority of treated patients, along with secondary findings on fat quality; these trials used tesamorelin as a single agent, not combined with ipamorelin. [1]
02
Ipamorelin alone, human pharmacology
A pharmacokinetic-pharmacodynamic study of ipamorelin given intravenously to healthy male volunteers found dose-proportional kinetics and measurable growth hormone release; this describes ipamorelin studied by itself, not in combination with tesamorelin. [2]
03 · Numbers in context
What does dosing evidence actually support?
No study of the combined tesamorelin-plus-ipamorelin product exists in the sources reviewed. Tesamorelin's clinical dosing evidence comes from HIV lipodystrophy trials using the single-agent approved drug; ipamorelin's human data comes from a separate intravenous pharmacology study in healthy volunteers. Neither describes a validated protocol for a combined subcutaneous research vial.
A study dose is not a personal dose. Population, route, formulation and supervision are part of the result. Online community schedules are not treated here as established clinical protocols.
04 · Safety and limits
What not to overlook
- No trial data exists for this specific combination; tesamorelin's approved-drug evidence applies to a single-agent product for a defined indication, not this blend.
- Tesamorelin's approval is specific to HIV-associated lipodystrophy under medical supervision; the trials do not describe general use or combination with other secretagogues.
- Research-grade tesamorelin in this blend is not the approved Egrifta formulation.
- The supplier-stated combined milligram amount reflects a manufacturing specification, not a studied dose ratio.
05 · Product distinctions
Names are not interchangeable
Reign Peptide sells this as a single lyophilized powder vial containing both tesamorelin and ipamorelin at a supplier-stated total milligram amount (10mg or 20mg total per vial), reconstituted by the buyer for laboratory research use. This differs in formulation, regulatory status, and composition from the FDA-approved single-agent Egrifta product, and no independent ratio verification was reviewed for this page.
06 · Handling and storage
Follow validated product instructions
A single water volume, refrigerator temperature or expiry window cannot be assumed for every compound and formulation. Use the exact manufacturer documentation and a validated laboratory procedure. If stability, solvent compatibility or microbiological quality is not documented, those properties remain unverified.
Refrigeration, clear appearance and bacteriostatic water do not make an unverified research product suitable for injection. This guide does not provide a mixing or administration procedure.
The existing concentration calculator checks arithmetic only. It cannot choose a safe dose or establish compatibility, sterility or shelf life.
Reign Peptide · Business disclosure
Research product listings
Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.
Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.
Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.
Supplies and accessories
Compare the actual specifications
Jorge's supply directory includes syringes, alcohol pads, storage cases, travel refrigeration and electrolytes, with separate links for the two travel refrigeration options. Accessory availability is not a recommendation to administer a research compound.
Affiliate disclosure: As an Amazon Associate I earn from qualifying purchases.
Amazon affiliate link
Peptide fridge case
Listing: 63 slots for 3mL bottles, bag only. An organizer is not active refrigeration or a validated storage system.
View on Amazon ↗Amazon affiliate link
Peptide travel case
Medineed travel case with temperature display and two ice packs per listing. Check dimensions and transport requirements.
View on Amazon ↗Questions still worth asking
What remains unresolved?
- Would combining an approved GHRH analog with an unapproved secretagogue produce additive, synergistic, or unpredictable effects on growth hormone release compared with either alone?
- Has the specific ratio used in supplier blends like this one been evaluated for safety or pharmacokinetic interaction?
Check the source
References and evidence scope
- Human trial · 2017Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV ↗
- Human trial · 1999Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers ↗
These are the sources reviewed for this page, not an exhaustive systematic review. Related compound research is identified as such. Product links are not scientific references.
Keep reading